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Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in
Patients With Essential Thrombocythemia Age 40 to 59 Years
Without High-Risk Features
Anna L. Godfrey, Peter J. Campbell, Cathy MacLean, Georgina Buck, Julia Cook, Julie Temple, Bridget S. Wilkins,
Keith Wheatley, Jyoti Nangalia, Jacob Grinfeld, Mary Frances McMullin, Cecily Forsyth, Jean-Jacques Kiladjian,
Anthony R. Green, and Claire N. Harrison on behalf of the United Kingdom Medical Research Council Primary
Thrombocythemia-1 Study, the United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms
Subgroup, the French Intergroup of Myeloproliferative Neoplasms, and the Australasian Leukaemia and
Lymphoma Group.
A B S T R A C T
Purpose
Cytoreductive therapy is beneﬁcial in patients with essential thrombocythemia (ET) at high risk of
thrombosis. However, its value in those lacking high-risk features remains unknown. This open-
label, randomized trial compared hydroxycarbamide plus aspirinwith aspirin alone in patientswith ET
age 40 to 59 years and without high-risk factors or extreme thrombocytosis.
Patients and Methods
Patients were age 40 to 59 years and lacked a history of ischemia, thrombosis, embolism, hem-
orrhage, extreme thrombocytosis (platelet count $ 1,500 3 109/L), hypertension, or diabetes re-
quiring therapy. In all, 382 patients were randomly assigned 1:1 to hydroxycarbamide plus aspirin or
aspirin alone. The composite primary end point was time to arterial or venous thrombosis, serious
hemorrhage, or death from vascular causes. Secondary end points were time to ﬁrst arterial or
venous thrombosis, ﬁrst serious hemorrhage, death, incidence of transformation, and patient-
reported quality of life.
Results
After a median follow-up of 73 months and a total follow-up of 2,373 patient-years, there was no
signiﬁcant difference between the arms in the likelihood of patients reaching the primary end point
(hazard ratio, 0.98; 95% CI, 0.42 to 2.25; P = 1.0). The incidence of signiﬁcant vascular events was
low, at 0.93 per 100 patient-years (95% CI, 0.61 to 1.41). There were also no differences in overall
survival; in the composite end point of transformation to myeloﬁbrosis, acute myeloid leukemia, or
myelodysplasia; in adverse events; or in patient-reported quality of life.
Conclusion
In patients with ET age 40 to 59 years and lacking high-risk factors for thrombosis or extreme
thrombocytosis, preemptive addition of hydroxycarbamide to aspirin did not reduce vascular events,
myeloﬁbrotic transformation, or leukemic transformation. Patients age 40 to 59 years without other
clinical indications for treatment (such as previous thrombosis or hemorrhage) who have a platelet
count , 1,500 3 109/L should not receive cytoreductive therapy.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Essential thrombocythemia (ET) is a chronic
myeloid malignancy characterized by throm-
bocytosis and, in most patients, a somatic mu-
tation affecting JAK2 (50% to 60%), CALR (25%
to 35%), or MPL (5% to 10%). A major com-
plication is thrombosis, most frequently arterial.
High risk of thrombosis is associated with age
older than 60 years or history of prior
thrombosis1-3; other factors may include the
JAK2 V617F mutation, cardiovascular risk fac-
tors, or increased white cell count.4-6 Patients
have increased risk of hemorrhage, especially
with marked thrombocytosis, whereas platelet
count is not associated with thrombotic risk.5,7 A
minority of patients transform to myeloﬁbrosis
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(MF), acute myeloid leukemia (AML), myelodysplastic syndrome
(MDS), or polycythemia vera (PV).8
Patients with ET at high risk of thrombosis developed fewer
thrombotic events when treated with the cytoreductive agent
hydroxycarbamide.9 In the Primary Thrombocythemia-1 (PT-1)
high-risk study, the composite vascular end point of arterial
thrombosis, venous thrombosis, serious hemorrhage, or death
from vascular events was reduced in patients randomly assigned to
hydroxycarbamide compared with those who received anagrelide.8
Hydroxycarbamide therapy was associated with lower risks of
arterial thrombosis, serious hemorrhage, MF, and treatment in-
tolerance, which established hydroxycarbamide as ﬁrst-line
treatment for patients requiring cytoreduction. Aspirin reduced
the risk of thrombotic events in PV10 and, although prospective
data in ET are lacking, aspirin has been recommended to reduce
vascular risk.11,12
For patients with ET who lack features associated with high
vascular risk, the rate of thrombosis is low (, 2% per year),13,14 but
may be higher in the subgroup age 40 to 59 years.2On the basis of these
data, patients age 40 to 59 years were designated intermediate risk in
the PT-1 study. There are no randomized data indicating whether
cytoreductive therapy is of value in this group. Although some authors
suggest that hydroxycarbamide might increase the risk of AML or
nonhematologic malignancies,15,16 this has not been conﬁrmed.3,17,18
Moreover, the chronic disease course of these patients, with
complications that occur at a low rate but have major clinical con-
sequences, means that clinical studies should follow a substantial
cohort of patients over a prolonged time period. We report the results
of the PT-1 intermediate-risk prospective, randomized trial comparing
hydroxycarbamide plus aspirin with aspirin alone in patients with ET
age 40 to 59 years and lacking high-risk factors.
PATIENTS AND METHODS
Patients
Patients were recruited from 140 hospitals in the United Kingdom,
Ireland, Australia, France, and New Zealand between July 21, 1997, and
July 31, 2012. Research ethics committees in each country approved the
study protocol, and all participants gave written informed consent.
Eligible patients met Polycythemia Vera Study Group diagnostic
criteria for ET (listed in the Data Supplement) and were either newly
diagnosed or previously treated. Patients were classiﬁed as intermediate
risk if they were age 40 to 59 years and did not meet any high-risk criteria:
a history of ischemia, thrombosis, or embolism; hemorrhage caused by ET;
hypertension or diabetes requiring pharmacologic therapy; current or
previous platelet counts $ 1,000 3 109/L. The exclusion for extreme
thrombocytosis reﬂects the increased risk of hemorrhage associated with
acquired von Willebrand syndrome, such that cytoreduction is warranted
in these patients.5,12,19 During the study (on May 6, 2004), the upper limit
of the platelet count for eligibility was increased to 1,500 3 109/L.
Exclusion criteria are listed in the Data Supplement.
Randomly assigned 
(N = 382)
Assigned to aspirin alone
(n = 190)
Assigned to hydroxycarbamide + aspirin
(n = 192)
Ineligible (n = 14)
(n = 11)
(n = 7)
(n = 21)
(n = 5)
(all PV; n = 3)Incorrect diagnosis 
Incorrect risk group
Deaths
Lost to follow-up
Withdrew consent
Treatment changes
Started hydroxycarbamide
Started anagrelide
Reasons
Clinical event/symptoms
Lack of platelet control
Age 60 years
Patient choice
Multiple reasons
Other/unknown
176 included in analysis
14 excluded (incorrect diagnosis / risk group)
Ineligible (n = 10)
(n = 9)
(n = 10)
(n = 19)
(n = 5)
(PV; n = 1)Incorrect diagnosis
Incorrect risk group
Deaths
Lost to follow-up
Withdrew consent
182 included in analysis
10 excluded (incorrect diagnosis / risk group)
Treatment changes
Never started HC
Stopped HC without starting
other cytoreduction
Switched HC to a different
cytoreductive agent
Added anagrelide to HC
Reasons
Side effects
Clinical event
Lack of platelet control
Patient choice
Multiple reasons
Other/unknown 
(n = 82) (n = 39)
(n = 9)
(n = 13)
(n = 14)
(n = 3)
(n = 11)
(n = 1)
(n = 3)
(n = 10)
(n = 3)
(n = 11)
(n = 71)
(n = 11)
(n = 21)
(n = 21)
(n = 11)
(n = 1)
(n = 8)
(n = 20)
Fig 1. CONSORT diagram. Details of
patients randomly assigned, treated, and
followed up in the study. Data were not
collected regarding eligibility screening
before randomization. Changes to cyto-
reductive treatment are shown. In the
aspirin-alone arm, 71 patients started
hydroxycarbamide (HC) and 11 started
anagrelide; 23 patients subsequently re-
ceived one or more additional agents
(hydroxycarbamide [14], anagrelide [11],
interferon-alfa [1], thalidomide [1]). In the
hydroxycarbamide-plus-aspirin arm, nine
patients were randomly assigned to
hydroxycarbamide but never started it;
13 patients stopped hydroxycarbamide
without simultaneously starting a sec-
ond-line agent; 14 patients switched to
an alternative cytoreductive agent (ana-
grelide [12], interferon-alfa [1], busulphan
[1]), and 3 started anagrelide without
stopping hydroxycarbamide. PV, poly-
cythemia vera.
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Randomization
Eligible patients were randomly assigned in a 1:1 ratio to receive
aspirin alone or hydroxycarbamide plus aspirin. Patients were entered into
the trial by fax or by telephoning the Clinical Trial Service Unit (CTSU),
Oxford, United Kingdom, until June 23, 2010, and subsequently at the
Cambridge Clinical Trials Unit (CCTU), Cambridge, United Kingdom.
Random assignment was accomplished by the central computer at CTSU
and CCTU, using a minimization algorithm20 to ensure that equal numbers
of patients were allocated to each arm, overall and within subgroups of
previous treatment (none, aspirin only, cytoreductive therapy only, or both).
A random number generator was used to assign the initial patients, then by
minimization with a random component. At CTSU, treatment allocations
were assigned by the randomization program and communicated by staff to
the enrolling doctor or nurse by fax or telephone, followed by a conﬁrmation
letter to the responsible clinician. At CCTU random assignments and
treatment allocations were handled by fax to the treating clinician.
Procedures
The study was open label. Patients assigned to hydroxycarbamide plus
aspirin were treated with 0.5 to 2 g oral hydroxycarbamide once per day,
adjusted tomaintain platelet counts within the range of 200 to 4003 109/L. All
patients were advised to take aspirin 75 mg once per day (100 mg in
Australia) or an alternative antiplatelet agent if aspirin was contraindicated.
Visit frequency, which was at the physician’s discretion, was recommended
to be at a minimum of every 3 months. Details of principal end point
diagnoses and adverse events were recorded annually in both arms, and
quality-of-life data were recorded annually for the ﬁrst 5 years (European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire C30 [EORTC QLQ-C30], version 2).
Peripheral blood samples for central molecular analysis were col-
lected at trial entry from 259 patients for DNA extraction (Strangeways
Research Laboratory, Cambridge, United Kingdom) and screened for JAK2
V617F, CALR, and MPL mutations at the Department of Haematology,
University of Cambridge (described in the Data Supplement). For
177 patients, a bone marrow trephine biopsy performed at trial entry was
reviewed centrally by two hematopathologists for diagnostic accuracy
(123 patients had a peripheral blood smear provided).
Outcomes
The composite primary end point was time from random assignment
until the patient died as a result of thrombosis or hemorrhage or had
a serious hemorrhage or thrombotic event (see the Data Supplement).
Secondary end points were time to the ﬁrst arterial or venous thrombotic
event or to the ﬁrst serious hemorrhage; time to death; incidence of
transformation to MF, AML, MDS, or PV; and patient-reported quality of
life. Full end point deﬁnitions are listed in the Data Supplement. End
points that occurred before May 31, 2013, and were reported before
October 31, 2013, were validated after independent evaluation by two
clinicians who were blinded to the patients’ treatment assignments; this
included review of peripheral blood smears and/or bone marrow samples
for transformations to MF, AML, and MDS. The study chairman resolved
any disagreements.
Trial Oversight
Annual interim analyses, including details of primary and secondary
end points and unexpected or serious toxicities, were assessed by an in-
dependent data monitoring committee. Stopping guidelines stated that
a difference of at least three standard deviations in an interim analysis of
a major end point might be needed to justify halting or modifying the trial
prematurely (the Haybittle-Peto rule). The study was funded by the
Medical Research Council, United Kingdom, and Cancer Research UK.
The funders had no role in study design, data collection, analysis, or
interpretation, or writing the report. The corresponding author had full
access to all study data and had ﬁnal responsibility for the decision to
submit the report for publication.
Table 1. Baseline Characteristics of the Analysis Populations
Feature
Aspirin Alone
(n = 176)
Hydroxycarbamide Plus Aspirin
(n = 182)
No./Total No. %
Median
(10th-90th centile) Range No./Total No. %
Median
(10th-90th centile) Range
Demographics
Male sex 83 47 63 35
Age at entry, years 51 41-58 52 42-58
Disease duration, months 4.2 0.69-60 3.2 0.66-61
Newly diagnosed patients (ie, , 3 months) 76 43 87 48
Characteristics at diagnosis
Platelet count 3 109/L 764 599-1,010 750 594-1,070
Hemoglobin, g/L 143 126-162 140 125-159
White cell count 3 109/L 8.6 5.9-12.0 8.8 6.1-13.0
Neutrophil count 3 109/L 5.6 3.4-8.6 5.7 3.6-8.7
Palpable splenomegaly 7/161 4 5/171 3
Blood counts at trial entry
Platelet count 3 109/L 726 587-1,050 744 570-1,080
Hemoglobin, g/L 140 125-160 138 124-159
White cell count 3 109/L 8.5 5.6-12.2 8.2 5.9-11.8
Previous treatment
Hydroxycarbamide 18 10 19 10
Anagrelide 2 1 1 1
Busulphan 2 1 3 2
Interferon 1 1 4 2
Key driver mutations
JAK2 73/124 59 68/135 50
MPL 5/124 4 8/135 6
CALR 32/124 26 36/135 27
Triple negative 14/124 11 23/135 17
jco.org © 2018 by American Society of Clinical Oncology 3
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Statistical Analysis
Sample size was originally calculated based on the following: if the
primary end point were in the order of 4% per annum,2,6 detection of
a 50% reduction in complication rate (at 2P = .05, with 80% power) in
the hydroxycarbamide-plus-aspirin arm compared with the aspirin-
alone arm, the trial was estimated to require a sample size of 280 in
each arm observed for a median of 4 years. Based on the possibility of
a low event rate, a decision was made in November 2006 that a number-
needed-to-treat (NNT) calculation was more appropriate and to con-
tinue recruitment until 2012. This duration of follow-up would be the
maximum period of time required to generate either a signiﬁcantly
different treatment effect or a point estimate for the NNT to prevent one
primary end point per year of . 100, with 95% conﬁdence that NNT is
greater than 50.
Rates of the primary and secondary end points and treatment
changes were compared between arms on an intention-to-treat basis
using Kaplan-Meier curves and log-rank tests, with censoring at the time
of death, withdrawal from the study, or last visit for patients lost to
follow-up. For the quality-of-life analysis, EORTC QLQ-C30 summary
scores21 were calculated for each patient questionnaire and compared
between the arms using linear mixed effects models. Hemoglobin, white
cell, and platelet counts were analyzed for patients with at least four
blood count recordings available in the ﬁrst 120 months on the study by
using linear mixed effects models. Additional details are provided in the
Data Supplement.
RESULTS
Patients and Treatment
The PT-1 intermediate-risk trial randomly assigned 382 pa-
tients to receive aspirin alone (190 patients) or hydroxycarbamide
plus aspirin (192 patients) between July 21, 1997, and July 31, 2012
(Fig 1). Twenty-four patients who were identiﬁed after random
assignment to be ineligible for trial entry (incorrect diagnosis or
risk group) were excluded from the analysis (Fig 1). Median
duration of follow-up was 73 months (range, 0 to 187 months):
73 months in the aspirin-alone arm (range, 3 to 183 months) and
73 months in the hydroxycarbamide-plus-aspirin arm (range, 1 to
187 months). Total follow-up was 2,373 patient-years.
The two arms were well matched with respect to laboratory
and clinical features at diagnosis and trial entry (Table 1). Of the
259 patients with molecular information, 141 (54%) had a JAK2
V617F mutation, 68 (26%) a CALR mutation, 13 (5%) an MPL
mutation, and 37 (14%) none of these mutations. Of 177 patients
for whom a trephine biopsy at trial entry was reviewed centrally,
167 (94%) met British Committee for Standards in Haematology
diagnostic criteria for ET,11 other diagnoses being myeloprolif-
erative neoplasm, unclassiﬁable (5 patients) and primary MF
(5 patients). One hundred forty-three (81%) met WHO diagnostic
criteria for ET.22
Changes in cytoreductive treatment were permitted at the
discretion of the treating physician and are shown, with reasons, in
Figure 1. In the aspirin-alone arm, 82 (47%) of 176 patients in the
analysis population started a cytoreductive agent; the median time
without cytoreduction from trial entry (ie, time until treatment
change, death, consent withdrawal, loss to follow-up, or end of
trial) was 36 months. In the hydroxycarbamide-plus-aspirin arm,
39 (21%) of 182 patients in the analysis population had a change in
treatment, deﬁned as stopping hydroxycarbamide and/or starting
an alternative cytoreductive agent; the median time on trial
hydroxycarbamide from trial entry (ie, time until treatment
change, death, consent withdrawal, loss to follow-up, or end of
trial) was 55 months.
Vascular End Points and Death
Numbers of vascular events and deaths are provided in
Table 2. There was no signiﬁcant difference between the two arms
in the composite primary end point of time from random as-
signment to arterial or venous thrombosis, serious hemorrhage, or
death from vascular causes (11 events in each arm; odds ratio [OR]
for hydroxycarbamide plus aspirin compared with aspirin alone
was 0.98 [95% CI, 0.42 to 2.25; P = 1.0; Fig 2A, Table 2). The
incidence of these vascular events during follow-up was 0.93 per
100 patient-years (95% CI, 0.61 to 1.41 per 100 patient-years).
There remained no signiﬁcant difference in this end point in
a prespeciﬁed secondary analysis, in which patients were censored
Table 2. Number of Patients Reaching Principal Study End Points
Feature
Aspirin Alone
(n = 176)
Hydroxycarbamide
Plus Aspirin
(n = 182) P
Primary end point
Arterial or venous
thrombosis, serious
hemorrhage, or death
from thrombosis or
hemorrhage
11 11 1.0
Secondary end point
Arterial thrombosis 7 5
Myocardial infarction 2 0
Ischemic stroke 2 3
Transient ischemic attack 3 1
Small bowel infarction 0 1
Venous thromboembolism 3 4*
Deep vein thrombosis 1 3
Pulmonary embolism 2 2
Serious hemorrhage 2 3
Intracranial hemorrhage 1 2
GI hemorrhage 0 1
Postoperative major
hemorrhage†
1 0
Cause of death 7 10 .5
Thrombotic 2 2
Hemorrhagic 0 1
Hematologic‡ 2 3
Other 3 4
Transformation to: 6 5 .7
MF 5 1
AML† 2 3
MDS 0 1
PV 6 0 .01
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syn-
drome; MF, myeloﬁbrosis, PV, polycythemia vera.
*One patient suffered both deep vein thrombosis and pulmonary embolism.
†Deﬁned as requiring transfusion of at least two units of red cells.
‡All of the deaths that were a result of hematologic causes followed trans-
formation to AML.
§Of the two patients in the aspirin-alone arm who transformed to AML, both
received cytoreductive therapy. One started hydroxycarbamide 7 months after
trial entry and transformed to AML 10 months later. The second patient started
anagrelide 23 months after trial entry (on moving to the PT-1 high-risk arm),
switched to hydroxycarbamide 58 months later, developed MF after a further 13
months and AML after another 9 months. The four patients in the hydrox-
ycarbamide-plus-aspirin arm who developed AML or MDS transformed 62, 62,
65, and 106 months after trial entry and had received only hydroxycarbamide on
the study at the time of transformation.
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Fig 2. Kaplan-Meier curves for the (A) primary composite end point of arterial or venous thrombosis, serious hemorrhage, or death from vascular causes; (B) overall
survival; (C) composite end point of rate of transformation tomyeloﬁbrosis (MF), acutemyeloid leukemia (AML), or myelodysplastic syndrome (MDS); (D) transformation to
polycythemia vera (PV); (E) composite end point of any major disease-related complication (arterial thrombosis, venous thromboembolism, major hemorrhage, trans-
formation to AML, MDS, MF, or death from any of these causes). (F) Box plots showing summary scores for the European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C30 questionnaire, performed at baseline and annually for 5 years after study entry; there were no signiﬁcant differences between the
study arms at any time point. Box and whisker plot showing median and vertical whisker showing 2nd and 98th percentile. HC, hydroxycarbamide.
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on reaching the age of 60 years, because most would start
cytoreduction at this age if they were not already receiving it (OR,
0.54; 95% CI, 0.19 to 1.53; P = .3). There were no signiﬁcant
associations between the rate of the primary end point and the
presence of JAK2, CALR, orMPLmutations, age at trial entry, sex,
or blood counts at diagnosis (hemoglobin, white cell count, platelet
count; all P . .05; data not shown).
There were seven deaths during follow-up in the aspirin-alone
arm and 10 in the hydroxycarbamide-plus-aspirin arm (Table 2),
with no signiﬁcant difference in overall survival between the arms
(OR, 1.4; 95% CI, 0.54 to 3.61; P = .5; Fig 2B).
Disease Transformation and All Disease-Related
Complications
The rate of disease transformation was low in both arms
(Table 2). In the aspirin-alone arm, ﬁve patients developed
transformation to MF, two to AML (one after MF), and none
transformed to MDS. In the hydroxycarbamide-plus-aspirin arm,
one patient developed transformation to MF, three to AML, and
one to MDS. There was no signiﬁcant difference in the composite
end point of rate of transformation to MF, AML, or MDS (OR,
0.79; 95%CI, 0.24 to 2.58; P = .7; Fig 2C). In addition, six patients
in the aspirin-alone arm transformed to PV compared with none
in the hydroxycarbamide arm (P = .01; Fig 2D), in keeping with
the nonspeciﬁc effect of hydroxycarbamide in constraining
erythropoiesis. A prespeciﬁed analysis for any major disease-
related complication (ie, arterial thrombosis, venous thrombo-
embolism, major hemorrhage, transformation to AML, MDS, or
MF, or death from any of these causes) did not show any dif-
ference between the two arms (OR, 0.83; 95% CI, 0.41 to 1.7;
P = .6; Fig 2E).
Adverse Events and Quality of Life
There were no signiﬁcant differences between the arms of the
study in the numbers of patients with speciﬁc adverse events, either
when symptoms were considered individually or when grouped by
system (eg, gastroenterologic, dermatologic). Selected adverse
events are listed in Table 3. There were no signiﬁcant differences in
EORTC QLQ-C30 quality-of-life summary scores21 between the
arms at any year after study entry (Fig 2F).
Impact of Treatment Changes
Because patients in the aspirin-alone armwere more likely to
undergo a change in their allocation to cytoreductive therapy
(P , .001; Figs 1 and 3A), we considered the possibility that this
may have masked a difference between the arms. However the
primary end point continued to show no difference between the
arms in a post hoc analysis in which patients were censored at age
60 years or on the date of therapy initiation or change to their
cytoreductive treatment (OR, 0.72; 95% CI, 0.16 to 3.19; P = .7).
Moreover, hemoglobin levels, white cell counts, and platelet
counts were all signiﬁcantly lower in the hydroxycarbamide-plus-
aspirin arm from early in the study, and CIs started to overlap
only approximately 5 to 6 years after trial entry for platelet and
white cell counts and 3 to 4 years after trial entry for hemoglobin
(Fig 3B-D).
DISCUSSION
Previous studies have shown that, compared with no cytoreduction
or anagrelide, hydroxycarbamide reduces the risk of vascular events
in patients with high-risk ET.8,9 We report the only (to the best of
our knowledge) prospective, randomized study to have compared
treatment with and without cytoreduction in ET patients who lack
high-risk factors. Patients were recruited over a 15-year period, and
the median duration of follow-up was more than 6 years, with
a total follow-up of 2,373 patient years, making this study unique
within the ﬁeld.
This trial compared two treatment strategies in patients with
ETage 40 to 59 years who lacked high-risk factors and showed that
preemptive addition of hydroxycarbamide to aspirin did not re-
duce the risk of vascular events or myeloﬁbrotic or leukemic
transformation. Our data indicate that the risk of signiﬁcant
vascular events in this patient population is low and is not reduced
by preemptive hydroxycarbamide. There was also no association
between the primary end point and blood counts at diagnosis. This
speciﬁc group of patients should therefore be treated without
cytoreduction until another clinical indication arises.
It has been suggested that hydroxycarbamide may increase the
risk of leukemic transformation,15 although this proposal remains
controversial.3,17,18,23 Our results contribute the only data from
a prospective, randomized trial comparing hydroxycarbamide with
no cytoreduction in the myeloproliferative neoplasms in patients
who lack high-risk features. Rates of transformation to MF, AML,
Table 3. Number of Patients Who Reported Adverse Events
Adverse Event
Aspirin Alone
(n = 176)
Hydroxycarbamide
Plus Aspirin
(n = 182)
Gastroenterologic
Diarrhea 3 3
Nausea or vomiting 1 5
Abdominal pain or indigestion 9 5
Gastritis or peptic ulcer 2 3
Constipation 1 2
Other 6 11
Dermatologic
Rash 1 5
Leg ulcer 2 4
Mouth ulcers 4 4
Other 5 3
Hematologic (excluding transformations)
Iron deﬁciency anemia 6 3
Other anemia 1 2
Other 4 3
Other systems
Constitutional symptoms* 6 8
Peripheral vascular disease 2 3
Minor hemorrhage 26 25
Nonhematologic cancer† 10 13
NOTE. There were no statistically signiﬁcant differences between the arms.
*Constitutional symptoms included fatigue, lethargy, weight loss, loss of
appetite, fevers, night sweats.
†No. of occurrences: aspirin-alone arm: melanoma (3), breast (2), myeloma (2),
ovary (1), renal (1), and brain (1) and in the hydroxycarbamide plus aspirin arm:
colorectal (2), lung (2), ovary (2), breast (1), larynx (1), esophagus (1), non-
melanoma skin cancer (1), liver (1), leiomyosarcoma (1), and unknown primary (1).
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and MDS were low, with no signiﬁcant difference between the two
arms over the course of the study. Hydroxycarbamide was also well
tolerated; only 6% of patients allocated to the drug discontinued it
as a result of adverse effects.
Limitations of this study reﬂect the fact that myeloproliferative
neoplasms, most particularly ET, have a chronic course and so
require long-term clinical trials. Such trials face inherent chal-
lenges, including predictable accumulation of changes to allocated
treatment over time and the evolution of diagnostic criteria and
risk stratiﬁcation models. Long-term follow-up was important in
this study because events can occur late in the disease, but long-
term follow-up was reﬂected in changes in the risk proﬁle of some
patients during the study. Many patients in the aspirin-alone arm
started cytoreduction during follow-up as a consequence of ac-
cepted clinical indications; similarly, some patients allocated to
hydroxycarbamide plus aspirin changed or stopped cytoreduction
during the study. Despite these changes, the primary end point
showed no difference between the arms in a post hoc analysis with
censoring at the time of treatment change, and blood counts
remained signiﬁcantly different between the arms for several years
after trial entry. Treatment changes do, however, limit the con-
clusions that can be drawn about the long-term safety of
hydroxycarbamide. A second limitation of the study is that a small
number of patients were recruited at each center. We suspect that
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Fig 3. Treatment changes and blood counts during follow-up. (A) Kaplan-Meier curves showing changes from the allocated trial treatment (ie, patients in the aspirin-alone
arm who started cytoreduction and patients in the hydroxycarbamide [HC]-plus-aspirin arm who stopped hydroxycarbamide and/or started an alternative cytoreductive
agent). (B) Platelet counts, (C) white cell counts, and (D) hemoglobin levels during the study; mean and 95%CIs are shown. Baseline counts were not signiﬁcantly different
between the two arms (Table 1). The high density of early blood counts and the rapid change after starting hydroxycarbamide means that the spline curves of blood count
data generate the false impression of a difference between the two arms at baseline, which is in fact not present. Treatment changes are shown as ticks below the x-axis.
HC, hydroxycarbamide.
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any selective recruitment was most likely to reﬂect the uncertain
beneﬁts and toxicities of hydroxycarbamide in this group of pa-
tients without previous disease complications, and we would not
expect the generalizability of the results to be affected.
Diagnostic criteria for ET have been reﬁned many times over
the 15-year recruitment period of this study.11,22,24 Nonetheless,
a high degree of concordance with current diagnostic criteria was
observed on central review of diagnostic material. Concerning
risk stratiﬁcation, the platelet threshold that deﬁnes high-risk
disease has changed from 1,000 3 109/L to 1,500 3 109/L,11,12
and the inclusion criteria of the study were modiﬁed accordingly.
The recently proposed International Prognostic Score of
Thrombosis in World Health Organization-essential thrombo-
cythemia (IPSET-thrombosis) system suggests that patients with
ET who are younger than age 60 years and who lack a prior
thrombotic history could be subdivided into very-low-risk and
low-risk groups according to the absence and presence, re-
spectively, of a JAK2 mutation.25 It has been proposed that pa-
tients with a very low IPSET-thrombosis score might not require
aspirin therapy,26 but this was not tested in our study. We did not
identify a difference in vascular events between JAK2-mutated
and -unmutated patients, in contrast to other studies,27,28 per-
haps reﬂecting the low number of events and that molecular data
were not available for all patients. Our data do not support
preemptive cytoreduction, even in the subgroup of JAK2-mutated
patients, in the absence of high-risk factors.
In conclusion, preemptive addition of hydroxycarbamide to
aspirin did not reduce the risk of vascular events, myeloﬁbrotic
progression, or leukemic transformation in ET patients age 40 to
59 years who lacked high-risk factors for thrombosis or extreme
thrombocytosis. Patients age 40 to 59 years without other clinical
indications for treatment (such as previous thrombosis or hem-
orrhage) who have a platelet count , 1,500 3 109/L should not
receive cytoreductive therapy.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Peter J. Campbell, Georgina Buck, Keith
Wheatley, Mary Frances McMullin, Anthony R. Green, Claire N. Harrison
Collection and assembly of data: Anna L. Godfrey, Peter J. Campbell,
Cathy MacLean, Georgina Buck, Julia Cook, Julie Temple, Bridget S.
Wilkins, Jyoti Nangalia, Jacob Grinfeld, Cecily Forsyth, Jean-Jacques
Kiladjian, Anthony R. Green, Claire N. Harrison
Data analysis and interpretation: Anna L. Godfrey, Peter J. Campbell,
Georgina Buck, Keith Wheatley, Jyoti Nangalia, Jacob Grinfeld, Jean-
Jacques Kiladjian, Anthony R. Green, Claire N. Harrison
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. [No authors listed]: Polycythemia vera: The
natural history of 1213 patients followed for 20 years:
Gruppo Italiano Studio Policitemia. Ann Intern Med
123:656-664, 1995
2. Cortelazzo S, Viero P, Finazzi G, et al: In-
cidence and risk factors for thrombotic complications
in a historical cohort of 100 patients with essential
thrombocythemia. J Clin Oncol 8:556-562, 1990
3. Marchioli R, Finazzi G, Landolﬁ R, et al: Vas-
cular and neoplastic risk in a large cohort of patients
with polycythemia vera. J Clin Oncol 23:2224-2232,
2005
4. Barbui T, Finazzi G, Carobbio A, et al: Devel-
opment and validation of an International Prognostic
Score of thrombosis in World Health Organization-
essential thrombocythemia (IPSET-thrombosis).
Blood 120:5128-5133, 2012
5. Campbell PJ, MacLean C, Beer PA, et al:
Correlation of blood counts with vascular complica-
tions in essential thrombocythemia: Analysis of the
prospective PT1 cohort. Blood 120:1409-1411, 2012
6. Besses C, Cervantes F, Pereira A, et al: Major
vascular complications in essential thrombocythe-
mia: A study of the predictive factors in a series of
148 patients. Leukemia 13:150-154, 1999
7. Carobbio A, Antonioli E, Guglielmelli P, et al:
Leukocytosis and risk stratiﬁcation assessment in
essential thrombocythemia. J Clin Oncol 26:2732-2736,
2008
8. Harrison CN, Campbell PJ, Buck G, et al:
Hydroxyurea compared with anagrelide in high-risk
essential thrombocythemia. N Engl JMed 353:33-45,
2005
9. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hy-
droxyurea for patients with essential thrombocy-
themia and a high risk of thrombosis. N Engl J Med
332:1132-1136, 1995
10. Landolﬁ R, Marchioli R, Kutti J, et al: Efﬁcacy
and safety of low-dose aspirin in polycythemia vera.
N Engl J Med 350:114-124, 2004
11. Harrison CN, Bareford D, Butt N, et al:
Guideline for investigation and management of
adults and children presenting with a thrombocy-
tosis. Br J Haematol 149:352-375, 2010
12. Barbui T, Barosi G, Birgegard G, et al:
Philadelphia-negative classical myeloproliferative
neoplasms: Critical concepts and management rec-
ommendations from European LeukemiaNet. J Clin
Oncol 29:761-770, 2011
13. Ruggeri M, Finazzi G, Tosetto A, et al: No
treatment for low-risk thrombocythaemia: Results from
a prospective study. Br J Haematol 103:772-777, 1998
14. Alvarez-Larra´n A, Pereira A, Guglielmelli P,
et al: Antiplatelet therapy versus observation in low-
risk essential thrombocythemia with a CALR muta-
tion. Haematologica 101:926-931, 2016
15. Sterkers Y, PreudhommeC, Laı¨ JL, et al: Acute
myeloid leukemia and myelodysplastic syndromes
following essential thrombocythemia treated with
hydroxyurea: High proportion of cases with 17p de-
letion. Blood 91:616-622, 1998
16. Hansen IO, Sørensen AL, Hasselbalch HC:
Second malignancies in hydroxyurea and interferon-
treated Philadelphia-negative myeloproliferative neo-
plasms. Eur J Haematol 98:75-84, 2017
17. Bjo¨rkholm M, Derolf AR, Hultcrantz M, et al:
Treatment-related risk factors for transformation to
acute myeloid leukemia and myelodysplastic syn-
dromes inmyeloproliferative neoplasms. J Clin Oncol
29:2410-2415, 2011
18. Tefferi A, Rumi E, Finazzi G, et al: Survival and
prognosis among 1545 patients with contemporary
polycythemia vera: An international study. Leukemia
27:1874-1881, 2013
19. Budde U, van Genderen PJ: Acquired von
Willebrand disease in patients with high platelet
counts. Semin Thromb Hemost 23:425-431, 1997
20. White SJ, Freedman LS: Allocation of patients
to treatment groups in a controlled clinical study. Br J
Cancer 37:849-857, 1978
21. Giesinger JM, Kieffer JM, Fayers PM, et al:
Replication and validation of higher order models
demonstrated that a summary score for the EORTC
QLQ-C30 is robust. J Clin Epidemiol 69:79-88, 2016
22. Swerdlow SH, Campo E, Harris NL, et al (eds):
WHO Classiﬁcation of Tumours of Haematopoietic
and Lymphoid Tissues. Lyon, France, IARC Press,
2008
23. Hanft VN, Fruchtman SR, Pickens CV, et al:
Acquired DNA mutations associated with in vivo
hydroxyurea exposure. Blood 95:3589-3593, 2000
24. Vardiman JW, Harris NL, Brunning RD: The
World Health Organization (WHO) classiﬁcation of
the myeloid neoplasms. Blood 100:2292-2302, 2002
25. Haider M, Gangat N, Lasho T, et al: Validation
of the revised International Prognostic Score of
Thrombosis for Essential Thrombocythemia (IPSET-
thrombosis) in 585 Mayo Clinic patients. Am J He-
matol 91:390-394, 2016
8 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Godfrey et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on September 11, 2018 from 147.188.108.179
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
26. Barbui T, Vannucchi AM, Buxhofer-Ausch V,
et al: Practice-relevant revision of IPSET-
thrombosis based on 1019 patients with WHO-
deﬁned essential thrombocythemia. Blood Cancer
J 5:e369, 2015
27. Rumi E, Pietra D, Ferretti V, et al: JAK2 or
CALRmutation status deﬁnes subtypes of essential
thrombocythemia with substantially different clini-
cal course and outcomes. Blood 123:1544-1551,
2014
28. Rotunno G, Mannarelli C, Guglielmelli P,
et al: Impact of calreticulin mutations on clini-
cal and hematological phenotype and outcome in
essential thrombocythemia. Blood 123:1552-1555,
2014
Affiliations
Anna L. Godfrey, Jacob Grinfeld, and Anthony R. Green, Cambridge University Hospitals National Health Service (NHS)
Foundation Trust; Peter J. Campbell and Jyoti Nangalia, Wellcome Trust Sanger Institute, Hinxton; Cathy MacLean, Julia Cook, Julie
Temple, and Anthony R. Green, University of Cambridge; Anthony R. Green, Wellcome Trust-Medical Research Council Cambridge
Stem Cell Institute, Cambridge; Georgina Buck, University of Oxford, Oxford; Bridget S. Wilkins and Claire N. Harrison, Guy’s and St
Thomas’ NHS Foundation Trust, London; Keith Wheatley, University of Birmingham, Birmingham; Mary Frances McMullin, Queen’s
University Belfast, Belfast, United Kingdom; Cecily Forsyth, Gosford Hospital, Gosford, and Australasian Leukaemia and Lymphoma
Group, Australia; and Jean-Jacques Kiladjian, Hoˆpital Saint-Louis, Paris, France
Support
Supported by theMedical Research Council, United Kingdom, Cancer Research UK, the French National Cancer Institute, Bloodwise,
Wellcome Trust, the Kay Kendall Leukaemia Fund, and the Leukemia and Lymphoma Society of America.
Prior Presentation
Presented at the 59th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 9-12, 2017.
n n n
jco.org © 2018 by American Society of Clinical Oncology 9
Hydroxycarbamide in Intermediate-Risk Essential Thrombocythemia
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on September 11, 2018 from 147.188.108.179
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Anna L. Godfrey
Travel, Accommodations, Expenses: Novartis Pharmaceuticals UK
Peter J. Campbell
No relationship to disclose
Cathy MacLean
No relationship to disclose
Georgina Buck
No relationship to disclose
Julia Cook
Employment: Amgen (I)
Stock or Other Ownership: Amgen (I)
Julie Temple
Employment: Dermal Laboratories
Bridget S. Wilkins
Honoraria: Novartis
Travel, Accommodations, Expenses: Novartis
Keith Wheatley
Research Funding: Novartis (Inst)
Jyoti Nangalia
No relationship to disclose
Jacob Grinfeld
No relationship to disclose
Mary Frances McMullin
Honoraria: Novartis, Celgene
Consulting or Advisory Role: Novartis, Italpharma
Travel, Accommodations, Expenses: Novartis, Celgene
Cecily Forsyth
Honoraria: Novartis, Celgene, Roche, Amgen, Bristol Myers Squibb,
Alexion Pharmaceuticals
Consulting or Advisory Role: Celgene, Novartis, Amgen, Roche
Jean-Jacques Kiladjian
Consulting or Advisory Role: Novartis, AOP Orphan Pharmaceuticals,
Celgene
Research Funding: Novartis (Inst), AOP Orphan Pharmaceuticals (Inst)
Travel, Accommodations, Expenses: Gilead Sciences
Anthony R. Green
No relationship to disclose
Claire N. Harrison
Honoraria: Gilead Sciences, Celgene, Novartis, Shire, CTI BioPharma,
AOP Orphan Pharmaceuticals, Genentech
Speakers’ Bureau: Novartis, CTI BioPharma, Shire, Gilead Sciences,
Incyte
Research Funding: Novartis (Inst)
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Godfrey et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on September 11, 2018 from 147.188.108.179
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank the clinicians and patients who participated in the study. Full details of participating sites and clinicians are listed in the Data
Supplement.
jco.org © 2018 by American Society of Clinical Oncology
Hydroxycarbamide in Intermediate-Risk Essential Thrombocythemia
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on September 11, 2018 from 147.188.108.179
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
